Contact
searchSearch
HMP Global
Login

Multiple Myeloma

News
The Efficacy and Safety of Teclistamab Among Patients With Relapsed or Refractory MM
08/07/2026
Rebecca Amrick
Researchers found that teclistamab was associated with better survival outcomes but increased rates of infection among patients with relapsed and refractory multiple myeloma (RRMM), showcasing how therapies could create a choice between...
Researchers found that teclistamab was associated with better survival outcomes but increased rates of infection among patients with relapsed and refractory multiple myeloma (RRMM), showcasing how therapies could create a choice between...
Researchers found that...
08/07/2026
Journal of Clinical Pathways
News
High-Risk Features Impact Patient Survival in Relapsed or Refractory MM
07/27/2026
Rebecca Amrick
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk...
07/27/2026
Journal of Clinical Pathways
News
Patients With Functional High-Risk MM Could Benefit from Early Receipt of T-Cell Therapy
07/21/2026
Rebecca Amrick
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining...
07/21/2026
Journal of Clinical Pathways
News
Evolutions in Frontline Treatment Patterns for Newly Diagnosed MM
07/15/2026
Rebecca Amrick
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a...
07/15/2026
Journal of Clinical Pathways
News
CAR T Therapy Demonstrates Improved Efficacy but Increased Toxicity in Patients With Relapsed or Refractory MM
06/22/2026
Rebecca Amrick
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR)...
06/22/2026
Journal of Clinical Pathways
News
High-Volume Facilities Are Linked to Improved Survival Outcomes for Patients With MM
06/09/2026
Rebecca Amrick
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are...
06/09/2026
Journal of Clinical Pathways
News
Geographic Distribution Creates Disparities in Access to MM CAR T Care Centers
06/03/2026
Rebecca Amrick
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of...
06/03/2026
Journal of Clinical Pathways
News
Type 2 Diabetes Prevention May Reduce the Risk of Diffuse Large B-cell Lymphoma and Multiple Myeloma
05/26/2026
Rebecca Amrick
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations...
05/26/2026
Journal of Clinical Pathways
News
Improving Geriatric Care for Older Patients With MM
05/20/2026
Rebecca Amrick
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have...
05/20/2026
Journal of Clinical Pathways
News
Dexamethasone Prophylaxis is a Promising Intervention Therapy for Patients With RRMM Receiving Cilta-Cel
05/15/2026
Rebecca Amrick
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows...
05/15/2026
Journal of Clinical Pathways
News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways

Expert Insights

Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways
Robert Rifkin, MD
Videos
Utilizing Real-World Data to Assess the Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma
12/21/2022
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his...
12/21/2022
Journal of Clinical Pathways
Thomas Martin, MD, UCSF
Interview
Isatuximab Plus Carfilzomib and Dexamethasone for Relapsed MM: Results From the IKEMA Trial
03/30/2022
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses...
03/30/2022
Journal of Clinical Pathways
Christopher Kim, Amgen
Videos
Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM
01/11/2022
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH,...
01/11/2022
Journal of Clinical Pathways
Videos
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
03/05/2021
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO,...
03/05/2021
Journal of Clinical Pathways
Videos
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
12/20/2020
12/20/2020
Journal of Clinical Pathways
Videos
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
12/09/2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD,...
12/09/2020
Journal of Clinical Pathways
ENGAGING EXPERTS
Comparative Effectiveness of KRd Versus VRd for Newly Diagnosed MM
08/27/2020
08/27/2020
Journal of Clinical Pathways
Guest Blog
Navigating the Labyrinth of Multiple Myeloma Treatment
04/24/2018
Thomas Marsland, MD
Thomas Marsland, MD, medical oncology, St Joseph Health (Petaluma, CA), discusses the many considerations related to initial therapy, transplantation, maintenance, and salvage therapy for patients with multiple myeloma.
Thomas Marsland, MD, medical oncology, St Joseph Health (Petaluma, CA), discusses the many considerations related to initial therapy, transplantation, maintenance, and salvage therapy for patients with multiple myeloma.
Thomas Marsland, MD, medical...
04/24/2018
Journal of Clinical Pathways
Headshot of Joe DePinto
Interview
Expanding Cell and Gene Therapy Adoption in Oncology Care
11/03/2026
Joe DePinto
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto...
11/03/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
Improving Therapy Options and Patient Experiences in NSCLC: Part 2
10/21/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu...
10/21/2026
Journal of Clinical Pathways
Rob Helton
Interview
Embedding Genomic Data, Clinical Guidelines, and Payer Requirements Into Community Oncology Workflows
10/19/2026
Rob Helton, DPT
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how...
10/19/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
Improving Therapy Options and Patient Experiences in NSCLC: Part 1
10/13/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu...
10/13/2026
Journal of Clinical Pathways
Gary Simmons, DO, MSHA
Interview
Expanding CAR T-Cell Therapy Access in Community Oncology
09/29/2026
Gary L. Simmons, DO
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA,...
09/29/2026
Journal of Clinical Pathways
Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how...
07/06/2026
Journal of Clinical Pathways

Newsfeed

News
High-Risk Features Impact Patient Survival in Relapsed or Refractory MM
07/27/2026
Rebecca Amrick
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk...
07/27/2026
Journal of Clinical Pathways
News
Patients With Functional High-Risk MM Could Benefit from Early Receipt of T-Cell Therapy
07/21/2026
Rebecca Amrick
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining...
07/21/2026
Journal of Clinical Pathways
News
Evolutions in Frontline Treatment Patterns for Newly Diagnosed MM
07/15/2026
Rebecca Amrick
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a...
07/15/2026
Journal of Clinical Pathways
News
CAR T Therapy Demonstrates Improved Efficacy but Increased Toxicity in Patients With Relapsed or Refractory MM
06/22/2026
Rebecca Amrick
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR)...
06/22/2026
Journal of Clinical Pathways
News
High-Volume Facilities Are Linked to Improved Survival Outcomes for Patients With MM
06/09/2026
Rebecca Amrick
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are...
06/09/2026
Journal of Clinical Pathways
News
Geographic Distribution Creates Disparities in Access to MM CAR T Care Centers
06/03/2026
Rebecca Amrick
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of...
06/03/2026
Journal of Clinical Pathways
News
Type 2 Diabetes Prevention May Reduce the Risk of Diffuse Large B-cell Lymphoma and Multiple Myeloma
05/26/2026
Rebecca Amrick
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations...
05/26/2026
Journal of Clinical Pathways
News
Improving Geriatric Care for Older Patients With MM
05/20/2026
Rebecca Amrick
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have...
05/20/2026
Journal of Clinical Pathways
News
Dexamethasone Prophylaxis is a Promising Intervention Therapy for Patients With RRMM Receiving Cilta-Cel
05/15/2026
Rebecca Amrick
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows...
05/15/2026
Journal of Clinical Pathways
News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways
News
Insurance Restrictions and High Costs Limit Blood Cancer Treatment Access
10/14/2026
Grace Taylor, MS, MA
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that...
10/14/2026
Journal of Clinical Pathways
News
EOM Lung Patient Pilot Associated With Reduced Emergency Care Utilization
10/09/2026
Rebecca Amrick
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model...
10/09/2026
Journal of Clinical Pathways
News
MYLUNG Study Links Timely Biomarker Testing to Improved Outcomes in mNSCLC
09/29/2026
Rebecca Amrick
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study...
09/29/2026
Journal of Clinical Pathways
News
Comprehensive Molecular Profiling Linked to Improved Survival in NSCLC
09/28/2026
Grace Taylor, MS, MA
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive...
09/28/2026
Journal of Clinical Pathways
Conference Coverage
Innovations in Relapsed or Refractory Multiple Myeloma Management
09/21/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
Managing Treatment Toxicity Among Patients With Chronic Myeloid Lymphoma
09/21/2026
Rebecca Amrick
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC,...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
De-Escalating TKI Therapy Based on Risk and Response for Patients With CML
09/18/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive...
09/18/2026
Journal of Clinical Pathways
News
Anemia Associated With Higher Mortality and AML Transformation Risk in Myelofibrosis
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
Enhanced Financial Assistance Associated With Improved Radiotherapy Completion
09/08/2026
Rebecca Amrick
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing...
09/08/2026
Journal of Clinical Pathways
News
Molecular Testing Improves Survival Outcomes for Patients With Endometrial Cancer, Study Finds
09/03/2026
Rebecca Amrick
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing...
09/03/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Safety and Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
04/06/2022
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with multiple myeloma to those seen in clinical trials.
True or False: In the real-world...
04/06/2022
Journal of Clinical Pathways
Quiz
Quiz: Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM
12/01/2021
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve progression-free survival and depth of response, compared to no consolidation in patients with newly...
True or False: Consolidation...
12/01/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Belantamab Mafodotin for Relapsed/Refractory MM
10/14/2021
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab mafodotin is cost-effective compared to selinexor plus dexamethasone, for patients with relapsed/refractory multiple myeloma who have received 4 or more therapies.
True or False: Belantamab...
10/14/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Daratumumab for MM
09/09/2021
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding daratumumab to bortezomib, melphalan, and prednisone for the treatment of newly diagnosed multiple myeloma is not considered cost-effective.
True or False: Adding...
09/09/2021
Journal of Clinical Pathways
Quiz
Quiz: Daratumumab Among Patients With MM
07/19/2021
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based regimens are an effective treatment option for multiple myeloma across all lines therapy, presenting the strongest response in the first-line setting.
True or False: Daratumumab-based...
07/19/2021
Journal of Clinical Pathways
Quiz
Quiz: DRd vs Rd for Newly Diagnosed MM
03/12/2021
03/12/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use